Oppenheimer Confident in Positive PROSERA Trial Readout in February 2026 for Gossamer Bio (GOSS)

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the stocks that will double in 2026. On December 9, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Gossamer Bio, with a price target of $15.

Earlier on November 10, Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Gossamer Bio to $12 from $9 with an Outperform rating on the shares following the company’s announcement of its Q3 2025 earnings results.

Oppenheimer is highly confident about the upcoming topline readout for the PROSERA trial in February 2026. This confidence is supported by the baseline characteristics of the PROSERA study population and the positive results previously reported in the Phase 2 TORREY data, which collectively increase the probability of PROSERA achieving its primary endpoint of statistically significant improvement in the 6-Minute Walk Distance. Furthermore, the company has successfully activated the first clinical site for the Phase 3 SERANATA/PH-ILD trial, with results from this pivotal study currently anticipated in 2027.

In other news, Gossamer Bio reported a revenue of $13.3 million in Q3 2025 earlier, which includes $9.2 million of cost reimbursement revenue from its global collaboration with the Chiesi Group, significantly surpassing the estimated $6.33 million. However, the net loss for the quarter was $48.2 million, or a $0.21 basic net loss per share, which was below the estimated loss of $0.18 per share. This was a wider loss compared to the net loss of $30.8 million, or $0.14 per share, recorded in Q3 2024.

Gossamer Bio Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company that develops and commercializes seralutinib for the treatment of pulmonary arterial hypertension/PAH in the US.

While we acknowledge the potential of GOSS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.